- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01908270
Effects of Yoga on Menopausal Symptoms in Women With Breast Cancer
July 30, 2014 updated by: Holger Cramer, Universität Duisburg-Essen
Randomized Controlled Trial of Yoga for Menopausal Symptoms in Women With Breast Cancer
Women with breast cancer and breast cancer survivors are often bothered by menopausal symptoms to a special degree.
Treatment options for those symptoms are currently limited as hormone replacement therapy is often prohibited.
Yoga has been shown to reduce menopausal symptoms as well as symptoms associated with breast cancer.
Therefore, this study aims to investigate whether a 12-week yoga intervention can reduce menopausal symptoms in women with breast cancer and breast cancer survivors.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Essen, Germany, 45276
- Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Breast cancer (Stage I-III)
- After completion of surgical therapy
- After completion of adjuvant radiotherapy and chemotherapy
- Score of 5 or greater on the Menopausal Rating Scale
- Physical and cognitive capacity to participate in the yoga intervention
- Willingness to participate in 10 or more of the 12 yoga interventions
- signed informed consent
Exclusion Criteria:
- Regular yoga practice in the past 12 months
- Planned surgery in the study period
- Diagnosed and medically treated psychosis
- Hormone replacement therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Usual care
Patients continue usual care by their practitioner
|
|
|
Experimental: Yoga
Yoga intervention 12 weeks, weekly 90-minute intervention Yoga postures, breathing, relaxation, and meditation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Menopausal symptoms
Time Frame: Week 12
|
Menopause Rating Scale
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse events
Time Frame: Week 12
|
Week 12
|
|
|
Health-related quality of life (disease-specific)
Time Frame: Week 12
|
Functional Assessment of Cancer Therapy - Breast
|
Week 12
|
|
Fatigue
Time Frame: Week 12
|
Functional Assessment of Chronic Illness Therapy - Fatigue
|
Week 12
|
|
Anxiety
Time Frame: Week 12
|
Hospital Anxiety and Depression Scale
|
Week 12
|
|
Depression
Time Frame: Week 12
|
Hospital Anxiety and Depression Scale
|
Week 12
|
|
Menopausal symptoms
Time Frame: Week 24
|
Menopause Rating Scale
|
Week 24
|
|
Health-related quality of life (disease-specific)
Time Frame: Week 24
|
Functional Assessment of Cancer Therapy - Breast
|
Week 24
|
|
Fatigue
Time Frame: Week 24
|
Functional Assessment of Chronic Illness Therapy - Fatigue
|
Week 24
|
|
Anxiety
Time Frame: Week 24
|
Hospital Anxiety and Depression Scale
|
Week 24
|
|
Depression
Time Frame: Week 24
|
Hospital Anxiety and Depression Scale
|
Week 24
|
|
Adverse events
Time Frame: Week 24
|
Week 24
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Appraisal of body
Time Frame: Week 12
|
Fragebogen zur Beurteilung des Körpers (Questionnaire for the assessment of body)
|
Week 12
|
|
Appraisal of body
Time Frame: Week 24
|
Fragebogen zur Beurteilung des Körpers (Questionnaire for the assessment of body)
|
Week 24
|
|
Body awareness
Time Frame: Week 12
|
Body Awareness Questionnaire
|
Week 12
|
|
Body awareness
Time Frame: Week 24
|
Body Awareness Questionnaire
|
Week 24
|
|
Self-esteem
Time Frame: Week 12
|
Self-esteem scale
|
Week 12
|
|
Self-esteem
Time Frame: Week 24
|
Self-esteem scale
|
Week 24
|
|
Adherence
Time Frame: Week 12
|
Course adherence and daily home practice
|
Week 12
|
|
Adherence
Time Frame: Week 24
|
Daily home practice
|
Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Holger Cramer, PhD, Department of Internal and Integrative Medicine, Kliniken Essen-Mitte, Faculty of Medicine, University of Duisburg-Essen
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2013
Primary Completion (Actual)
November 1, 2013
Study Completion (Actual)
February 1, 2014
Study Registration Dates
First Submitted
July 23, 2013
First Submitted That Met QC Criteria
July 24, 2013
First Posted (Estimate)
July 25, 2013
Study Record Updates
Last Update Posted (Estimate)
July 31, 2014
Last Update Submitted That Met QC Criteria
July 30, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13-5421-BO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
University of Colorado, DenverCompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerCanada
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Mayo ClinicMarker Therapeutics, Inc.CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
Clinical Trials on Usual care
-
Charite University, Berlin, GermanyCompletedMultiple Sclerosis | FatigueGermany
-
Charite University, Berlin, GermanyMammazentrum Hamburg am Krankenhaus Jerusalem, Germany; Dorit und Alexander...Completed
-
European Institute for Evidence Based Osteopathic...Unknown
-
Suzanna ZickUniversity of MichiganTerminatedQuality of Life | Fatigue | Lupus Erythematosus, Systemic | Sleep | Pain, ChronicUnited States
-
Centers for Disease Control and PreventionCompleted
-
University Hospital, MontpellierCompletedOsteoarthritis | Mindfulness | MBSRFrance
-
Gachon University Gil Oriental Medical HospitalKorea Health Industry Development InstituteCompletedKnee Replacement | AcupunctureKorea, Republic of
-
Mayo ClinicCompleted
-
The Miriam HospitalNational Institute on Aging (NIA)CompletedHeart FailureUnited States
-
Lawson Health Research InstituteUnknownDepression | Quality of Life | Sleep | Anxiety | Dry EyeCanada